LELarisa G. Ermolaeva

Larisa G. Ermolaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Larisa G. Ermolaeva has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Atrial fibrillation in sepsis and the potential effects of propafenone and levocarnitine

    by N. Yu. Semigolovskii, S. O. Mazurenko, L. G. Ermolaeva, E. V. Balukova, S. N. Semigolovskii, Н. Ю. Семиголовский, С. О. Мазуренко, Л. Г. Ермолаева, Е. В. Балукова, С. Н. Семиголовский

    Actually sepsis is one of the most important health problems, as the incidence of it in the world is high and continues to grow, and mortality reaches 40–60%, especially with the development of septic shock. Frequent heart damage in sepsis – septic cardiomyopathy (an established term for sepsis-caused by acute cardiac dysfunction syndrome unrelated to ischemia due to damage to the coronary arteries) – is often complicated by the occurrence of cardiac arrhythmias. Ventricular arrhythmias are rare, and atrial fibrillation develops in 20–30% of cases, reaching 45% with septic shock. At the same time, mortality increases by about 2–3 times if attempts at cardioversion are unsuccessful. However, the issues of antiarrhythmic therapy have not yet been regulated. The Russian and Eurasian clinical guidelines for the treatment of atrial fibrillation (2025) do not mention sepsis. And the recommendations of the European Society of Cardiology and the Association of Cardiothoracic Surgeons (2024), supplemented by the European Heart Rhythm Association (2025), only state that sepsis is a trigger for atrial fibrillation and a risk factor for its subsequent recurrence in almost half of the discharged patients with sepsis, and the degree of inflammation correlates with the frequency of its development and recurrence. Drugs commonly used for cardioversion – beta-blockers, calcium antagonists, amiodarone – can worsen the situation, negatively affecting the hemodynamics of septic patients, especially in shock. The culprits of the hipotensive effect of amiodarone, in particular, are due of the emulsifier polysorbate-80 and benzyl alcohol in its composition. Based on an analysis of current clinical studies and our own clinical experience, the article examines the use of propafenone in this case, devoid of cardiodepressive properties. It is also advisable to use levocarnitine adjuvantly, which has positive inotropic and antioxidant properties, as well as being able to resist inflammatory and proarrhythmic links in the pathogenesis of sepsis, and prevent recurrence.

  • Open Access

    Dilated Cardiomyopathy after Viral Infection in Young Patients: Case Reports

    by Ekaterina V. Balukova, Yuliya S. Belyaeva, Ilya A. Tuchin, Larisa G. Ermolaeva

    Dilated cardiomyopathy (DCM) is a severe myocardial disease characterized by marked dilation of the left ventricle or both ventricles and progressive heart failure. It is one of the leading indications for heart transplantation worldwide. The etiology of DCM is heterogeneous and includes both genetic predisposition and external factors, among which previous viral myocarditis plays a key role. However, establishing the exact etiology remains challenging, because verification of viral myocardial injury in routine clinical practice is associated with objective difficulties. This article presents two clinical cases of severe DCM in young patients after an acute respiratory viral infection. The development of end-stage heart failure refractory to medical therapy required advanced treatment modalities: heart transplantation was recommended for one patient, whereas the other underwent implantation of a cardiac contractility modulation (CCM) system. In addition, the disease course in the first patient was complicated by thromboembolism of segmental branches of the pulmonary arteries in both lungs. Maintaining a high level of clinical vigilance in patients presenting with nonspecific complaints such as dyspnea, weakness, pain, and chest discomfort after an acute respiratory viral infection is critically important, as early diagnosis and timely initiation of pathogenetic therapy for myocarditis may prevent structural myocardial changes and, consequently, irreversible dilation of the cardiac chambers.

  • Open Access

    Thrombocytopenia in COVID-19 patients: The role of fondaparinux and succinates in improving outcomes (exchange of experience)

    by N. Yu. Semigolovskii, V. A. Ratnikov, I. S. Simutis, A. V. Svetlikov, L. G. Ermolaeva, D. S. Salygina, M. S. Danilov, S. N. Semigolovskii, A. A. Gorokhov, M. S. Mazurenko

    As is known, the new coronavirus infection (NCI) COVID-19 is accompanied by coagulopathy, for the treatment of which heparins are widely used that can cause heparin-induced thrombocytopenia type 2 (HIT), complicated by paradoxical thrombosis. A considerable number of cases of sudden thrombosis after vaccination with Pfizer, Moderna, and Oxford–AstraZeneca vaccines was also described, caused by vaccine-induced “spontaneous HIT syndrome”. An analysis of the medical histories of hospitalized COVID-19 patients (a total of 3,455), showed an 8-fold increase in the frequency of severe thrombocytopenia (<100 × 109/l), compared with patients of the pre-Covid period, and approximately 25% of them can be attributed to the manifestation of HIT. The use of the original Rule of express HIT-diagnostics in the pre-Covid period (“100–5–100”) and the original Algorithm for HIT-treatment (includes the transition to the use of Fondaparinux and succinate-containing drugs), as shown by an earlier our study, made it possible to reduce the frequency of severe thrombotic complications and significantly improve the results of treatment in non-infectious patients. These Rule and Algorithm have been applied in patients with NCI since 2021. The use of these principles partly explains the 3-times decrease of in-hospital mortality in 2021, compared with 2020 (from 18.0% to 6.7%), that coincides with an increase in the use of Fondaparinux and succinate-containing preparations in hospital. Thus, the application of the described Rule and Algorithm in the treatment of patients with NCI COVID-19 increases the effectiveness of treatment and reduces hospital mortality.

  • Open Access

    Experience in the treatment of patients with pulmonary embolism using apixaban and ultrasound inhalations of unfractionated heparin

    by N. Yu. Semigolovskii, S. O. Mazurenko, I. S. Simutis, L. G. Ermolaeva, S. N. Semigolovskii

    Introduction. Pulmonary embolism (PE) is one of the leading causes of death even in hospitalized patients. The standard treatment results are disappointing. Since 2004, we have tested a new method for the treatment of hemodynamically insignificant PE (own patent RU2224525C1) by using unfractionated heparin (UFH) in ultrasound inhalations with a nebulizer, since 2014 – in combination with apixaban. Aim. To improve the treatment of PE. Materials and methods. The hospital mortality rate of 713 patients of the cardiac intensive care unit with hemodynamically insignificant PE (from January 1, 2002 to December 31, 2017) was studied. Since 2004, patients have received ultrasound UFH (5000 units twice a day). Since 2014, nebulased UFH has been supplemented with the use of apixaban (10 mg twice a day for 7 days and 5 mg twice a day thereafter). Results and discussion. There is a distinct tendency to the PE hospital mortality decrease, coinciding with the nebulased UFH use (illustrated by a diagram). Neither the systemic bleeding nor the heparin-induced thrombocytopenia were observed. Clinical cases show first reduction of perfusion disorders are seeing scintigraphicaly in 7 days. Unlike LMWH UFH is recommended in severe kidney damage and obesity, thus ultrasound technique has advantages in such patients. Conclusions. Nebulased UFH is an available, simple, safe and effective in treatmtnt of hemodynamically insignificant PE, especially with the use of apixaban. A real improvement in lung perfusion takes 1 week, as shown scintigraphically.


  • Open Access

    Hospital readmissions of patients with COVID-19: causes, features, outcomes

    by O. N. Potanina, S. A. Ayrapetyan, S. O. Mazurenko, V. V. Strizheletsky, L. S. Palchikova, N. A. Teplyakova, L. G. Ermolaeva, Iu. M. Gomon, N. Yu. Semigolovskii

    Introduction. On average, 10% of patients hospitalized due to new coronavirus infection (COVID-19) will be readmitted. To date, the reasons for readmission and the characteristics of these cases are not fully presented.The aim of the study was to analyze readmissions of COVID-19 patients to identify the causes of readmission, clinical features, examination data and treatment outcomes.Materials and methods. The study was performed retrospectively by using electronic records of the medical cases of the St. Petersburg City Hospital of St. George. Inclusion criteria: 1) the presence of two or more hospitalizations during 2020–2021; 2) COVID-19 confirmed by polymerase chain reaction within 14 days before or during the first hospitalization, or the detection of changes in the lungs with a high probability associated with COVID-19 during primary computed tomography. One hundred and two people met the specified criteria.Results. In 85% of cases, the cause of re-admission was symptoms of respiratory infection; in 13% – thrombotic events (pulmonary embolism, acute cerebrovascular accident, deep vein thrombosis of the lower extremities); 12% – severe pain syndrome of various localizations; 11% - infectious and inflammatory processes; 9% – antibiotic-associated diarrhea; 5% – atrial fibrillation and less often other pathologies. Patients with respiratory symptoms had a high degree of respiratory failure, an increase in the volume of affected lung tissue and an increase in the content of various markers of inflammation in the blood when compared with the data of the initial examination. Nine percent of patients died during hospitalization.Conclusions. The leading cause of repeated inpatient treatment of COVID-19 patients were symptoms of reactivation of the infection with a number of indicators of a greater severity of this “second wave” of the disease. Further studies are required to reduce the risk of repeated inpatient treatment.

  • Open Access

    The value of bone mineral density assessment by dual-energy x-ray absorptiometry for prediction of cardiovascular mortality in patients treated with hemodialysis

    by Sergey O. Mazurenko, Yakov A. Nakatis, Aleksander A. Enkin, Konstantin G. Staroselsky, Aleksander N. Vasiliev, Oksana G. Mazurenko, Petr V. Soin, Larisa G. Ermolaeva, Igor G. Ivanov, Васильев Александр Николаевич

    Aim. Determine whether bone mineral density (BMD) assessed by dual-energy x-ray absorptiometry can be used as predictor of increased risk of death in hemodialysis patients. Materials and methods. A prospective study was performed of 516 patients with chronic kidney disease treated with hemodialysis (men 265, women 251, mean age 44.811.4 years) who were observed for 5.73.2 years. Before inclusion in the study, in all patients was analyzed bone mineral density using dual-energy X-ray absorptiometry in three standard departments: lumbar vertebrae, proximal femur and distal forearm. The probability analysis of the outcome was carried out using the KaplanMeier method and Cox. Results. During follow-up period 111 (21.5%) patients died, 50.5% from cardiovascular events. Survival analysis by KaplanMeier method allowed to prove the increased risk of death from cardiovascular pathology in hemodailysis patients with low bone mineral density of all evaluated areas. Step-by-step multivariate Cox regression analysis showed that the T score of the femur, showing the difference of BMD of the patient with normal value of BMD for young adult, had the greatest prognostic significance. Conclusion. Reduced bone mineral density in patients receiving hemodialysis is associated with an increased risk of death from cardiovascular disease. Dual energy x-ray absorptiometry can be used for assessment of this risk.


  • The influence of nutritional status on the prognosis of patients receiving treatment with hemodialysis

    by Д. М. Крутько, S. O. Mazurenko, К. Г. Старосельский, L. G. Ermolaeva

    Влияние нутриционного статуса на прогноз пациентов, получающих лечение гемодиализом